ducovest

DGX:NYE-Quest Diagnostics Incorporated (USD)

COMMON STOCK | Diagnostics & Research |

Last Closing

USD 171.23

Change

0.00 (0.00)%

Market Cap

USD 19.12B

Volume

1.03M

Analyst Target

USD 138.69
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Quest Diagnostics Incorporated provides diagnostic testing and services in the United States and internationally. The company develops and delivers diagnostic information services, such as routine, non-routine and advanced clinical testing, anatomic pathology testing, and other diagnostic information services. It also provides diagnostic information services primarily under the Quest Diagnostics brand, as well as under the AmeriPath, Dermpath Diagnostics, ExamOne, and Quanum brands to physicians, hospitals, patients and consumers, health plans, government agencies, employers, emerging retail healthcare providers, pharmaceutical companies and insurers, commercial clinical laboratories, and accountable care organizations through a network of laboratories, patient service centers, phlebotomists in physician offices, call centers and mobile phlebotomists, nurses, and other health and wellness professionals. In addition, the company offers risk assessment services for the life insurance industry; and healthcare organizations and clinicians information technology solutions. Quest Diagnostics Incorporated was founded in 1967 and is headquartered in Secaucus, New Jersey.

Company Website : https://www.questdiagnostics.com

Currency: USD

Country : USA

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2025-05-24 )

Largest Industry Peers for Diagnostics & Research

Symbol Name Price(Change) Market Cap
DHR Danaher Corporation

N/A

 USD 140.35B
A Agilent Technologies Inc

N/A

 USD 32.44B
IQV IQVIA Holdings Inc

N/A

 USD 24.71B
LH Laboratory Corporation of Amer..

N/A

 USD 20.88B
QGEN Qiagen NV

N/A

 USD 9.05B
CRL Charles River Laboratories

N/A

 USD 6.92B
ENZ Enzo Biochem Inc

N/A

 USD 0.02B
TMO Thermo Fisher Scientific Inc

N/A

 N/A
WAT Waters Corporation

N/A

 N/A
MTD Mettler-Toledo International I..

N/A

 N/A

ETFs Containing DGX

EDOC:LSE Global X Telemedicine & D.. 4.68 % 0.00 %

N/A

 USD 4.27M
EDOG:LSE Global X Telemedicine & D.. 4.68 % 0.00 %

N/A

 USD 0.30M
EDOC:SW Global X Telemedicine & D.. 4.04 % 0.00 %

N/A

 N/A
SMIG ETF Series Solutions - AA.. 3.42 % 0.00 %

N/A

 USD 1.02B
OWLU:LSE 2.44 % 0.00 %

N/A

 N/A
RYH 0.00 % 0.40 %

N/A

 N/A
GERM 0.00 % 0.00 %

N/A

 N/A

Market Performance

  Market Performance vs. Industry/Classification (Diagnostics & Research) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 13.50% 100% F 88% B+
Dividend Return 1.03% 83% B 41% F
Total Return 14.53% 100% F 89% A-
Trailing 12 Months  
Capital Gain 21.20% 92% A 87% B+
Dividend Return 2.16% 86% B+ 42% F
Total Return 23.36% 100% F 87% B+
Trailing 5 Years  
Capital Gain 51.76% 82% B 58% F
Dividend Return 12.50% 100% F 32% F
Total Return 64.26% 82% B 53% F
Average Annual (5 Year Horizon)  
Capital Gain 4.39% 50% F 54% F
Dividend Return 6.32% 50% F 53% F
Total Return 1.93% 100% F 45% F
Risk Return Profile  
Volatility (Standard Deviation) 20.20% 75% C 49% F
Risk Adjusted Return 31.28% 75% C 49% F
Market Capitalization 19.12B 50% F 91% A-

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

Superior return on assets

The company management has delivered better return on assets in the most recent 4 quarters than its peers, placing it in the top quartile.

Superior capital utilization

The company management has delivered better return on invested capital in the most recent 4 quarters than its peers, placing it in the top quartile.

Superior return on equity

The company management has delivered better return on equity in the most recent 4 quarters than its peers, placing it in the top quartile.

Underpriced compared to earnings

The stock is trading low compared to its peers on a price to earning basis and is in the top quartile. It may be underpriced but do check its financial performance to make sure there is no specific reason.

Superior total returns

The stock has outperformed its sector peers on average annual total returns basis in the past 5 years (for a hold period of at least 12 months) and is in the top quartile.

Low volatility

The stock’s annual returns have been stable and consistent compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile. Although stability is good, also keep in mind it can limit returns.

Positive cash flow

The company had positive total cash flow in the most recent four quarters.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

Underpriced on free cash flow basis

The stock is trading low compared to its peers on a price to free cash flow basis and is in the top quartile. It may be underpriced but do check its financial performance to make sure there is no specific reason.

What to not like:
Highly leveraged

The company is in the bottom half compared to its sector peers on debt to equity and is highly leveraged. However, do check the news and look at its sector and management statements. Sometimes this is high because the company is trying to grow aggressively.

Overpriced on cashflow basis

The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Below median dividend returns

The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.

Low market capitalization

This is among the smaller entities in its sectors with below median market capitalization. That may make it less stable in the long run unless it has a unique technology or market which can help it grow or get acquired in future.

Low Earnings Growth

This stock has shown below median earnings growth in the previous 5 years compared to its sector

Low Dividend Growth

This stock has shown below median dividend growth in the previous 5 years compared to its sector.